The risk of becoming dependent or addicted to Oxicodona Sandoz varies from person to person. You may have a higher risk of becoming dependent or addicted to Oxicodona Sandoz if:
If you notice any of the following signs while taking Oxicodona Sandoz, it could be a sign that you have become dependent or addicted:
If you notice any of these signs, talk to your doctor to analyze the best treatment for you, including when it is appropriate to stop taking it and how to do it safely (see section 3, If you stop taking Oxicodona Sandoz).
The prolonged-release tablets should be administered with special caution in patients who have a history of drug and alcohol abuse.
Increased sensitivity to pain
There may be an increase in sensitivity to pain (hyperalgesia) that does not respond to an additional increase in the dose of oxicodona, especially at high doses. You may need to reduce the dose of oxicodona or switch to an alternative opioid.
In the case of abusive injection (injection into a vein), the excipients of the tablet may cause tissue destruction (necrosis), changes in lung tissue (pulmonary granulomas), or other potentially fatal effects.
Like other opioids, oxicodona may affect the normal production of hormones in the body, such as cortisol or sex hormones, particularly if you are taking high doses for a long period.
You may see residues of the tablet in your feces. Do not worry, as the active principle hydrochloride of oxicodona has already been released before, while the tablet passed through your gastrointestinal tract and has begun to be effective in your body.
Competitors should be aware that this medication may produce a positive result in anti-doping tests.
The use of oxicodona as a doping agent may be a health risk.
Inform your doctor or pharmacist if you are using, have used recently, or may need to use any other medication.
Taking oxicodona with certain medications that affect brain function (see below) may increase the risk of respiratory depression, especially in cases of overdose in elderly patients, and/or increase the sedative effect of oxicodona (you may feel very drowsy).
The concomitant use of oxicodona and medications that can affect brain function (e.g. sedatives such as benzodiazepines or related medications, see below) increases the risk of somnolence, respiratory depression, coma, and may be potentially fatal. Therefore, concomitant use should only be considered when other treatment options are not possible.
However, if your doctor prescribes oxicodona with sedatives, your doctor should limit the dose and duration of concomitant treatment. Inform your doctor of all sedatives you are taking and follow your doctor's recommended doses closely. It may be helpful to inform friends or family members to be aware of the symptoms and signs indicated above. Contact your doctor when you experience these symptoms.
Medications that affect brain function:
The risk of side effects increases if you are taking antidepressants (such as citalopram, duloxetine, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, or venlafaxine). These medications may interact with oxicodona and cause symptoms such as involuntary muscle contractions, agitation, excessive sweating, tremors, exaggerated reflexes, increased muscle tension, and a body temperature above 38°C. Contact your doctor if you experience these symptoms.
Other interactions may occur with:
Drinking alcohol during oxicodona treatment may make you feel drowsy or increase the risk of serious side effects such as shallow breathing with the risk of stopping breathing and loss of consciousness. It is recommended not to drink alcohol while taking oxicodona.
Drinking grapefruit juice while taking oxicodona may increase the risk of adverse reactions. You should avoid taking grapefruit juice during oxicodona treatment.
If you are pregnant or breastfeeding, consult your doctor or pharmacist before using this medication.
You should not takeoxicodonaduring pregnancy. There is limited data on the use ofOxicodona Sandozin pregnant women.
Oxicodona crosses the placenta into the fetal circulation.
Prolonged use of oxicodona during pregnancy may cause withdrawal symptoms in the newborn. Use of oxicodona during delivery may cause slow and shallow breathing (respiratory depression) in the newborn.
You should not take Oxicodona Sandoz if you are breastfeeding, as the active principle oxicodona may pass into breast milk and cause drowsiness (sedation) or slow and shallow breathing (respiratory depression) in the infant.
Oxicodona may affect your ability to drive and operate machinery.
In stabilized patients with a specific dose, it may not affect the driving restrictions, the doctor will make this decision based on each individual case. Consult your doctor, when, or under what conditions, you can drive a vehicle.
Oxicodona Sandoz contains lactose
This medication contains lactose. If your doctor has told you that you have an intolerance to certain sugars, consult with him before taking this medication.
Follow exactly the administration instructions of this medication indicated by your doctor. In case of doubt, consult your doctor or pharmacist again.
Before starting treatment and periodically during treatment, your doctor will talk to you about what you can expect from the use of Oxicodona Sandoz, when and for how long you should take it, when to contact your doctor and when to stop taking it (see also “If you interrupt treatment with Oxicodona Sandoz”).
Other concentrations of this medication may be available for dose adjustment.
Adults and adolescents (12 years and older)
The usual initial dose is 10 mg of hydrochloride of oxicodone at intervals of 12 hours. Your doctor will indicate the necessary dose to treat pain.
Take two times a day the amount of prolonged-release tablets determined by your doctor.
The subsequent determination of the daily dose, division into individual doses and any adjustment of the dose during the subsequent course of treatment, should be made by the doctor in charge of the treatment and taking into account previous doses.
Patients who have already taken opioids may start treatment with higher doses, taking into account their previous experience.
Some patients to whom oxicodone prolonged-release tablets are administered according to a fixed schedule, need rapid-acting analgesics as rescue medication to control breakthrough pain. Oxicodona prolonged-release tablets are not indicated for the treatment of breakthrough pain.
For the treatment of pain not due to cancer, a daily dose of 40 mg of hydrochloride of oxicodone is usually sufficient, but higher doses may be necessary.
Patients with pain due to cancer usually need daily doses of 80 to 120 mg of hydrochloride of oxicodone, which in some cases can be increased to 400 mg.
During treatment, the relief of pain and other effects should be regularly monitored to achieve the best possible pain treatment, as well as to be able to treat any adverse effect that occurs as soon as possible and decide whether to continue treatment.
Children under 12 years
This medication has not been studied in children under 12 years of age. Therefore, its safety has not been demonstrated and its use is not recommended in children.
Patients with renal and/or hepatic insufficiency
Your doctor may prescribe a lower initial dose.
Other high-risk patients
Your doctor may prescribe a lower initial dose if you have a low body weight or if you metabolize medications more slowly.
Administration form
Only by oral route.
Swallow the prolonged-release tablets whole with a sufficient amount of liquid (half a glass of water), with or without food, in the morning and in the afternoon following a fixed schedule (e.g. at 8 am and at 8 pm).
Prolonged-release tablets should not be divided, broken, crushed or chewed as this leads to rapid release of oxicodone due to alteration of the prolonged-release properties. Administration of broken, crushed or chewed tablets leads to rapid release and absorption of a potentially lethal dose of the active principle of oxicodone (see the section “If you take more Oxicodona Sandoz than you should”).
Oxicodone is only for oral administration. In case of abusive injection (intravenous injection), the excipients of the tablet may cause local tissue destruction (necrosis), changes in lung tissue (pulmonary granulomas) or other severe and potentially fatal effects.
If you have taken more oxicodone than you should, consult your doctor, pharmacist or call the Toxicological Information Service, phone: 91 562 04 20, indicating the medication and the amount ingested.
Symptoms of overdose may be:
In severe cases, loss of consciousness (coma), accumulation of fluid in the lungs and circulatory collapse that can be fatal may occur.
You should never expose yourself to situations that require a high level of concentration, such as driving.
If you use a lower dose of oxicodone than prescribed, or if you forget to take the tablets, the pain relief will be insufficient or will cease completely.
If you forget to take a dose, please follow these instructions:
Do not take more than one dose in an 8-hour period.
Do not take a double dose to compensate for missed doses.
Do not interrupt treatment without consulting your doctor.
When a patient no longer needs treatment with oxicodone, it may be advisable to gradually reduce the dose to prevent withdrawal symptoms (e.g. yawning, dilated pupils, lacrimation, nasal secretion, tremors, sweating, anxiety, restlessness, convulsions, difficulty sleeping or muscle pain).
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
The most common side effects are nausea (especially at the beginning of therapy) and constipation. Constipation caused by a side effect can be counteracted with preventive measures (such as drinking many liquids, a diet rich in fiber). If you experience nausea or vomiting, your doctor may prescribe a medication.
Side effects or important signs to be aware of and what to do if you are affected:
Stop taking oxicodone and consult your doctor or go to your nearest emergency center immediately if you experience any of the following symptoms:
Possible side effects
Very common(may affect more than 1 in 10 people),
Common(may affect up to 1 in 10 people)
Uncommon(may affect up to 1 in 100 people)
Rare(may affect up to 1 in 1,000 people)
Frequency not known(cannot be estimated from available data)
Reporting of side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through theSpanish System for Pharmacovigilance of Medicines for Human Use:https://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Do not use this medication after the expiration date that appears on the blister pack, bottle, and container after “CAD/EXP”. The expiration date is the last day of the month indicated.
No special storage conditions are required.
Bottles: Expiration after first opening:
6 months.
Medications should not be disposed of through drains or trash. Deposit the containers and medications you no longer need at the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of the containers and medications you no longer need. By doing so, you will help protect the environment.
Each prolonged-release tablet contains 40 mg of hydrochloride of oxicodona equivalent to 35.9 mg of oxicodona.
Tablet core: Hydrogenated ricin oil, copovidone, polioxyglycerides of behenoyl, lactose monohydrate, magnesium stearate, cornstarch, anhydrous colloidal silica, medium-chain triglycerides.
Prolonged-release tablets, coated with a yellow film, round, biconvex, 6.8 - 7.4 mm in diameter.
The prolonged-release tablets are packaged in child-resistant blisters or closed containers with a child-resistant Twist-off cap, with or without a desiccant capsule, containing silica gel as a desiccant.
Packaging sizes:
Blister: 10, 20, 28, 30, 40, 50, 56, 60, 100, and 112 prolonged-release tablets.
Containers: 50 and 100 prolonged-release tablets.
Only some packaging sizes may be commercially available.
Marketing authorization holder:
Sandoz Farmacéutica, S.A.
Centro Empresarial Parque Norte
Edificio Roble
C/ Serrano Galvache, 56
28033 Madrid
Spain
Lek Pharmaceuticals d.d
Verovskova 57,
1526 Ljubljana
Slovenia
or
Salutas Pharma GmbH
Otto-von-Guericke-Allee 1
39179 Barleben
Germany
Germany: Oxycodonhydrochlorid - 1 A Pharma 40 mg Retardtabletten
Belgium: Oxycodon Sandoz 40 mg tabletten met verlengde afgifte
Denmark: Oxycodone Depot Sandoz
Netherlands: Oxycodon HCl Sandoz retard 40mg, tabletten met verlengde afgifte
Sweden: Oxycodone Depot 1A Pharma 40 mg depottabletter
Slovenia: Codilek 40 mg tablete s podaljšanim sproščanjem
Slovakia: Contiroxil 40 mg tablety s predlženým uvolnovaním
United Kingdom
Northern Ireland: Carexil 40 MG Prolonged-release Tablets
Last reviewed date of the package insert: April 2025.
For detailed information about this medicine, please visit the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) http://www.aemps.gob.es/ .
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.